Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.

Conditions

• SARS-CoV-2 Infection

Interventions

• DRUG: RP7214 + Standard of care (SOC)
• DRUG: Placebo + Standard of care (SOC)

Sponsor

Rhizen Pharmaceuticals SA

Collaborators

• [object Object]